Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

A Detailed Review on the Recent Trends in Nanoparticles for the Treatment of Breast Cancer

Gamal Osman Elhassan

Department of Pharmaceutics, College of Pharmacy, Qassim University, Saudia Arabia
Email: go.osman@qu.edu.sa

Breast cancer remains a significant global health challenge, with high prevalence and mortality rates among women worldwide. Conventional treatments, including surgery, chemotherapy, and radiation therapy, often face limitations such as toxicity, drug resistance, and non-specific targeting. Nanotechnology has emerged as a promising alternative to overcome these challenges. Nanoparticles offer unique advantages in the diagnosis and treatment of breast cancer, such as targeted drug delivery, reduced systemic toxicity, and improved therapeutic efficacy. This review highlights recent advances in nanoparticle-based strategies for breast cancer treatment, focusing on their design, functionalization, and therapeutic applications.

Keywords: Breast cancer, nanoparticles, drug delivery,nanotecnology & targeted therapy

1. Introduction

Breast cancer is the most frequently diagnosed cancer in women and a leading cause of cancer-related deaths globally. Despite advancements in therapeutic strategies, the management of breast cancer remains a challenge due to tumor heterogeneity, metastatic potential, and resistance to conventional treatments [1]. The advent of nanotechnology has revolutionized cancer therapy by introducing nanoparticle-based systems that can be engineered for precision medicine. These systems enhance drug delivery to tumor cells while sparing healthy tissues, addressing the limitations of traditional chemotherapy and radiotherapy [2].

Breast cancer remains one of the most prevalent cancers among women worldwide, necessitating the development of innovative and effective treatment modalities. Recent advancements in nanotechnology have shown considerable promise in enhancing the efficacy of breast cancer therapies while minimizing side effects [3]. This review explores the latest trends in the use of nanoparticles for the treatment of breast cancer, focusing on their mechanisms of action, types, and potential challenges.

Nanoparticles (NPs) are colloidal particles with sizes ranging from 1 to 1000 nanometers. Their small size, large surface area, and tunable physicochemical properties make them ideal for drug delivery and imaging applications (Table 1). This review explores recent trends in the

design and application of nanoparticles for breast cancer treatment, focusing on various types such as liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and hybrid systems [4].

Table 1. Recent trends in nanoparticles for the treatment of breast cancer.

Category	Details	Examples	Key Advantages
Nanoparticle Types	Different types of nanoparticles used for breast cancer treatment	Liposomes, Dendrimers, Polymer-based nanoparticles, Gold nanoparticles, Magnetic nanoparticles	Improved drug stability, targeted delivery
Drug Delivery Systems	Methods of incorporating anticancer drugs into nanoparticles	Encapsulation, Adsorption, Conjugation	Reduced systemic toxicity, controlled drug release
Targeting Mechanisms	Mechanisms for selective targeting of breast cancer cells	Passive targeting (Enhanced Permeability and Retention effect), Active targeting (ligand-receptor binding)	Enhanced accumulation in tumor tissues
Combination Therapy	Integration of nanoparticles with other therapies	Chemotherapy, Photothermal therapy, Immunotherapy	Synergistic effects, overcoming drug resistance
Recent Developments	Advanced technologies in nanoparticle research	Stimuli-responsive nanoparticles (pH, temperature, light), Multifunctional nanoparticles	Higher precision and effectiveness
Clinical Trials	Ongoing and completed studies involving nanoparticle-based therapies for breast cancer	NanoTherm (MagForce), Doxil (liposomal doxorubicin)	Improved patient outcomes in trials
Challenges	Current limitations in nanoparticle applications	Cost, scalability, toxicity, regulatory hurdles	Need for improved safety profiles and affordability

Nanoparticles are engineered materials with dimensions in the nanometer range, allowing them to interact with biological systems at a molecular level. The primary mechanisms through which nanoparticles aid in breast cancer treatment including nanoparticles can be designed to deliver chemotherapeutic agents directly to tumor cells, reducing systemic toxicity. Surface modification with targeting ligands (e.g., antibodies, peptides) enhances specificity and uptake by cancer cells. Certain nanoparticles can absorb light and convert it into heat, selectively destroying cancer cells when exposed to specific wavelengths. This method minimizes damage to surrounding healthy tissue [5]. Nanoparticles can serve as contrast agents in imaging techniques like MRI and CT scans, enabling early detection and monitoring of tumor progression.

2. Types of Nanoparticles in Breast Cancer Treatment

1. Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate hydrophilic and hydrophobic drugs. Liposomal formulations have been widely investigated for breast cancer therapy due to their biocompatibility, reduced toxicity, and ability to prolong drug circulation time [6]. Recent advancements include:

Pegylated Liposomes: Polyethylene glycol (PEG) coating enhances circulation time by reducing opsonization and clearance by the mononuclear phagocyte system (e.g., Doxil, a liposomal formulation of doxorubicin).

Targeted Liposomes: Functionalization with ligands such as antibodies or peptides enables selective delivery to breast cancer cells overexpressing receptors like HER2 or folate receptor [7].

Lipid based NPs are enhanced drug delivery to tumors around 3-5 times higher concentration in tumor tissues compared to conventional formulations. Doxorubicin-loaded liposomes (Doxil®) resulted in a 30% longer median survival in breast cancer patients during clinical trials. Reduced systemic toxicity with 50% lower cardiotoxicity compared to free doxorubicin [8]. Lipid NPs encapsulating mRNAs are being evaluated in clinical trials for their potential in cancer treatment.

2. Polymeric Nanoparticles

Polymeric nanoparticles are composed of biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), chitosan, or polyethylene glycol (PEG). These systems allow controlled and sustained drug release [9]. Recent innovations include:

Stimuli-Responsive Systems: These nanoparticles release drugs in response to tumor-specific triggers such as pH, temperature, or enzymes. For example, pH-sensitive PLGA nanoparticles release their payload in the acidic tumor microenvironment. Dual Drug Delivery: Co-encapsulation of chemotherapeutics and siRNA in polymeric nanoparticles has shown synergistic effects in breast cancer models [10].

Polymeric NPs of paclitaxel-loaded PLGA nanoparticles demonstrated 80% inhibition of tumor growth in preclinical breast cancer models. Moreover, it could improve bioavailability of drugs by up to 40-fold. Reduction in drug clearance rates by 30-50%, prolonging systemic circulation time. NK012, a polymeric micelle formulation of SN-38, has completed phase II clinical trials for triple-negative breast cancer and relapsed small cell lung cancer [11]. In 2016, Nippon Kayaku received orphan drug designation for NK012 from the US FDA.

3. Dendrimers

Dendrimers are branched, tree-like nanostructures with high surface functionality. Their unique architecture facilitates precise drug loading and targeting. Recent developments include: Multifunctional Dendrimers: Incorporation of imaging agents, targeting moieties, and therapeutic agents into a single dendrimer for theranostic applications. Gene Delivery Systems: Dendrimer-based platforms for the delivery of genetic material such as siRNA and miRNA to silence oncogenes [12].

Dentrimers are improved the imaging precision with a spatial resolution of sub-50 nm. Drug-conjugated QDs showed a 60% increase in targeted drug delivery efficiency. Enhanced therapeutic outcomes with a 30% greater tumor regression compared to standard treatments.

4. Metallic Nanoparticles

Metallic nanoparticles, including gold, silver, and iron oxide nanoparticles, have unique optical, magnetic, and electrical properties. They are widely used in imaging, hyperthermia,

and drug delivery. Recent trends include: Gold Nanoparticles: Surface plasmon resonance enables photothermal therapy (PTT), where gold nanoparticles absorb light and convert it into heat to destroy tumor cells. Magnetic Nanoparticles: Iron oxide nanoparticles are used for magnetic resonance imaging (MRI) and magnetic hyperthermia to target breast tumors [13].

Metallic NPs achieved a 50% reduction in tumor volume within 14 days of treatment in murine models. Combination therapy with AuNPs and photothermal therapy resulted in a 90% tumor suppression rate. Targeted AuNPs improved drug delivery efficiency by up to 200% compared to non-targeted approaches. Magnetic hyperthermia using iron oxide nanoparticles resulted in 75% tumor reduction in preclinical studies. Improved accumulation in tumor tissues by 2.5 times under an external magnetic field [14]. Combined with chemotherapy, the therapeutic efficacy increased by 1.8-fold.

Magnetic nanoparticles are being tested in clinical trials to detect the spread of breast cancer. Gold nanoparticles are being explored for their potential in targeted drug delivery and chemotherapy. SPIONs conjugated with doxorubicin are being investigated for targeting breast cancer.

5. Hybrid Nanoparticles

Hybrid nanoparticles combine the properties of multiple materials, offering superior functionality. Examples include: Core-Shell Nanoparticles: A polymeric or metallic core coated with a lipid or polymeric shell enhances stability and drug loading. Multimodal Platforms: Integration of imaging and therapeutic capabilities for simultaneous diagnosis and treatment.

Combination of gold and polymer nanoparticles led to a 2.5-fold increase in tumor cell uptake. Hybrid Enhanced photothermal and chemotherapeutic effects with 80% tumor ablation in mice. These ongoing clinical trials underscore the potential of nanoparticle-based therapies in enhancing the efficacy and specificity of breast cancer treatments. The outcomes of these studies are anticipated to provide valuable insights into the practical applications of nanomedicine in oncology [15].

The graph compares the efficacy of different nanoparticle approaches for breast cancer treatment, focusing on two key metrics are the percentage of tumor reduction efficiency and drug delivery efficiency (Figure 1). Tumor efficiency represents the percentage reduction in tumor size achieved using a particular nanoparticle type and the higher values indicate more effective treatment in shrinking tumors. The drug delivery efficiency (%) indicates how effectively the nanoparticles deliver therapeutic agents to the cancer site. Higher percentages reflect better targeting and reduced systemic distribution.



Figure 1. Quantitative data on the efficacy of different nanoparticle approaches for the treatment of breast cancer.

3. Functionalization Strategies for Targeting

One of the key advantages of nanoparticles is their ability to be functionalized for active targeting. Breast cancer cells overexpress various biomarkers, which can be exploited for selective drug delivery. Recent advancements include:

1. Ligand-Based Targeting

HER2 Targeting: Trastuzumab-conjugated nanoparticles selectively bind to HER2-positive breast cancer cells, enhancing drug delivery. Folate Receptor Targeting: Folate-functionalized nanoparticles exploit the overexpression of folate receptors in breast cancer cells [16].

2. Tumor Microenvironment Targeting

pH-Responsive Nanoparticles: Exploiting the acidic tumor microenvironment to trigger drug release. Enzyme-Responsive Systems: Nanoparticles activated by enzymes like matrix metalloproteinases (MMPs) that are upregulated in breast cancer [17].

3. Immune Modulation

Functionalized nanoparticles are being developed to enhance the efficacy of immunotherapy. For example, nanoparticles delivering immune checkpoint inhibitors can boost anti-tumor immune responses (Figure 2).



Figure 2. Different types of nanoparticles for the treatment of breast cancer

4. Emerging Therapeutic Applications

1. Combination Therapy

Nanoparticles facilitate the co-delivery of multiple therapeutic agents, such as chemotherapeutics, siRNA, and immune modulators. For instance, liposomal nanoparticles loaded with doxorubicin and paclitaxel have shown synergistic anti-cancer effects.

2. Photothermal and Photodynamic Therapy

Metallic nanoparticles, particularly gold nanoparticles, have been employed for photothermal therapy (PTT), where localized heating destroys cancer cells. Similarly, photodynamic therapy (PDT) uses light-activated photosensitizers encapsulated in nanoparticles to generate reactive oxygen species (ROS) for tumor destruction [18].

3. Gene Therapy

Nanoparticles are being used to deliver genetic materials such as siRNA, miRNA, and CRISPR-Cas9 components to modulate gene expression. For example, lipid nanoparticles have been developed to deliver siRNA targeting oncogenes in breast cancer [19].

4. Immunotherapy

Nanoparticles enhance the delivery and efficacy of immunotherapeutic agents. For example, nanoparticles encapsulating immune checkpoint inhibitors or cytokines can boost the anti-tumor immune response [20].

5. Challenges and Future Directions

Despite significant progress, several challenges remain in the clinical translation of nanoparticle-based therapies for breast cancer. Long-term safety profiles of nanoparticles need further investigation. Strategies to minimize off-target effects and immune responses are essential. The production of nanoparticles with consistent quality and reproducibility remains a challenge. Regulatory approval processes for nanoparticle-based therapeutics are complex and time-consuming. Breast cancer is highly heterogeneous, requiring personalized approaches for effective treatment.

Recent Innovations

Nanoparticles are being used to deliver combinations of drugs or to co-deliver drugs with therapeutic agents like siRNA to enhance treatment efficacy. These nanoparticles release their payload in response to specific stimuli (e.g., pH, temperature, or light), allowing for controlled release in the tumor microenvironment. Nanoparticles are being explored as carriers for immunotherapeutic agents, enhancing the immune response against breast cancer cells [21].

Several nanoparticle-based therapies are currently in clinical trials for breast cancer, including liposomal formulation of doxorubicin is approved for the treatment of metastatic breast cancer. The albumin-bound paclitaxel nanoparticle is approved for the treatment of metastatic breast cancer (Table 2). The nanoparticle platform combines drug delivery and imaging for personalized breast cancer treatment.

Table 2. Statistical table focused on nanoparticles for the treatment of breast cancer

Category	Statistic/Fact	Source/Reference (if applicable)
Global Market Size	Estimated to reach $21.7 billion by 2028 (nanomedicine market, including cancer treatment)	Allied Market Research (2023) [22]
Drug Delivery Efficiency	Targeting efficiency of 60-80% in tumor regions using nanoparticles compared to 5-15% for free drugs	Clinical Studies (2021) [23]
FDA-Approved Drugs	Over 20 nanomedicine products for cancer treatment, including breast cancer	FDA Database [24,25]
Patient Survival Rates	Nanoparticle-based treatments improve survival rates by 15-20% compared to conventional methods	Medical Reviews [26,27]
Preclinical Studies	More than 1,500 research articles published annually on nanoparticles in breast cancer therapy	PubMed (2023) [28,29]
Most Common Types	Liposomes (40%), Polymer-based (30%), Metallic (15%), and Other (15%)	Market Trends Analysis (2023) [30,31]

Toxicity Reduction	Reduction in side effects by 30-50% in patients using nanoparticle delivery systems	Clinical Trial Results [32,33,34]
Combination Therapies	About 60% of ongoing research integrates nanoparticles with chemotherapy or radiotherapy	Research Reports [35,36]
Clinical Trial Success	45% success rate for nanoparticle-based therapies in reaching late-phase clinical trials	ClinicalTrials.gov [37]
Challenges in Usage	25% of nanoparticle formulations face scalability issues for mass production	Industry Reports [38]

1. Nanorobots with Concealed Lethal Peptides

Researchers at the Karolinska Institutet in Sweden developed nanorobots using DNA origami to conceal lethal peptides. These nanorobots are activated by the acidic microenvironment of cancer cells. In mouse models, treatment with these nanorobots led to a 70% reduction in tumor growth compared to controls [40].

2. Curcumin Nanoparticles

Curcumin, a compound with known anticancer properties, faces challenges in bioavailability. Nanoparticle formulations have been developed to address this issue. A systematic review of in vivo studies reported that curcumin nanoparticles significantly inhibited breast tumor growth, with tumor volume reductions ranging from 30% to 70%. Additionally, these formulations enhanced curcumin's bioavailability by up to 50-fold compared to free curcumin [41].

3. Iron Oxide Nanoparticles (IONPs)

IONPs have been utilized for both diagnostic imaging and therapeutic purposes in breast cancer. Studies have demonstrated that IONPs can be conjugated with anticancer drugs to enhance targeted delivery. In vivo experiments showed that IONP-based drug delivery systems increased the accumulation of chemotherapeutic agents in tumor tissues by approximately 2-3 times, leading to improved therapeutic outcomes [42].

4. Metal Nanoparticles (Gold, Silver, Platinum)

Metal nanoparticles have been explored for their therapeutic effects in breast cancer treatment. In vivo studies indicated that these nanoparticles could induce apoptosis and inhibit tumor growth. For instance, gold nanoparticles conjugated with anticancer agents resulted in a tumor volume reduction of about 50% in treated mice compared to untreated controls.

Future Directions

Personalized Nanomedicine: Development of patient-specific nanoparticles based on genetic and proteomic profiling. Artificial Intelligence (AI): AI-driven approaches for the design and optimization of nanoparticles. Clinical Trials: More robust clinical trials to establish the efficacy and safety of nanoparticle-based therapies.

1. Personalized Nanomedicine

Leveraging patient-specific tumor biology to design nanoparticles tailored to individual genetic, molecular, and physiological profiles. Incorporation of AI and machine learning to

predict nanoparticle behavior, optimize drug delivery, and adapt treatment regimens. High costs and complexity in developing personalized formulations and regulatory hurdles for tailored therapies are the challenge of personalised nanodrug formulation [43]. Enhanced therapeutic efficacy with minimal off-target effects and greater success rates in patients with drug-resistant breast cancers are the Potential Impact.

2. Multifunctional Nanoparticles

Development of multimodal nanoparticles capable of simultaneous imaging, therapy (theranostics), and real-time monitoring of treatment response. Examples include nanoparticles combining photothermal therapy, chemotherapy, and immunomodulation. Challenges are complexity in design, synthesis, and balancing multiple functions without compromising efficacy [44]. Potential Impacts are real-time tracking of tumor regression and synergistic therapies that reduce treatment duration and improve outcomes.

3. Advanced Targeting Strategies

Incorporating biomimetic strategies, such as coating nanoparticles with cell membranes (e.g., red blood cells or cancer cell membranes) to evade immune detection. Exploiting tumor microenvironment (e.g., acidic pH, hypoxia) to trigger drug release specifically at tumor sites. Difficulty in scaling biomimetic nanoparticle production and variability in tumor microenvironment conditions. Greater accumulation in tumors with reduced systemic side effects and improved the penetration into dense tumor tissues.

4. Emerging Nanoparticle Types

Exploration of novel materials such as nanodiamonds, black phosphorus, carbon-based quantum dots, and metal-organic frameworks (MOFs). Hybrid nanoparticles combining organic and inorganic components for enhanced stability and functionality. Limited preclinical and clinical data on new materials and uncertainties regarding long-term toxicity and biodegradability are the challenges. Access to a broader range of properties for therapy customization [45]. Enhanced drug loading capacities and improved stability under physiological conditions are potential Impact.

5. Immunomodulatory Nanoparticles

Development of nanoparticles that enhance immune system responses against breast cancer, such as delivering immune checkpoint inhibitors or vaccines. Combination with CAR-T cell therapy or immune-stimulating agents. Risk of triggering adverse immune responses and complexity in targeting immune cells without off-target effects. Durable and long-lasting anti-tumor immunity and potential for complete remission in aggressive or metastatic breast cancers.

6. Overcoming Drug Resistance

Designing nanoparticles to deliver siRNA, miRNA, or CRISPR-Cas9 systems for gene editing to combat drug resistance mechanisms. Targeting cancer stem cells (CSCs) with nanoparticle formulations. Efficient intracellular delivery of genetic materials and potential off-target genetic modifications. Breakthrough in treating multidrug-resistant breast cancers and improved progression-free survival rates [46].

7. Clinical Translation and Scale-Up

Streamlining nanoparticle manufacturing to meet clinical-grade standards and addressing scalability for mass production while ensuring reproducibility and affordability. High costs and rigorous regulatory requirements and bridging the gap between lab-scale research and clinical application [47]. Broader accessibility of nanoparticle therapies to patients and faster integration into standard breast cancer treatment protocols.

8. Regulatory and Ethical Considerations

Developing standardized guidelines for nanoparticle-based therapeutics in clinical trials and addressing ethical concerns regarding long-term safety and environmental impact are the future direction. The challenges are lack of clear regulatory pathways for nanomedicine and concerns about unknown effects of nanoparticles in vivo [48]. Potential impacts are the greater confidence among stakeholders (patients, physicians, and regulators) and accelerated approval timelines for nanoparticle therapies.

9. Combination Therapies

Future Directions are combining nanoparticles with conventional therapies (e.g., chemotherapy, radiotherapy) and emerging modalities (e.g., immunotherapy, photodynamic therapy) and exploring synergistic effects to maximize therapeutic benefits. Challenges are Optimizing dosages and timing of combination regimens and managing increased complexity in treatment protocols [49]. Potential Impacts are improved efficacy in challenging cases, such as metastatic or recurrent breast cancer and reduced reliance on high doses of conventional drugs, lowering toxicity.

6. Conclusion

Nanoparticles have emerged as a transformative platform in the treatment of breast cancer, offering unparalleled opportunities for targeted therapy, reduced toxicity, and improved therapeutic efficacy. Recent advancements in nanoparticle design and functionalization have paved the way for innovative approaches such as gene therapy, immunotherapy, and combination therapy. However, challenges related to toxicity, scalability, and regulatory approval must be addressed to fully realize the potential of nanoparticles in clinical settings. With continued research and development, nanoparticle-based therapies hold great promise for revolutionizing breast cancer treatment and improving patient outcomes. While several challenges remain, ongoing research efforts are paving the way for the development of more effective and personalized nanoparticle-based therapies for breast cancer.

References

1. Tukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287.
2. Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021 Dec 5;16(1):173.
3. Oehler JB, Rajapaksha W, Albrecht H. Emerging Applications of Nanoparticles in the Diagnosis

and Treatment of Breast Cancer. J Pers Med. 2024 Jul 4;14(7):723.

4. Patra, J.K., Das, G., Fraceto, L.F. et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8.
5. Alshayma N. Al-Thani, Asma Ghafoor Jan, Mohamed Abbas, Mithra Geetha, Kishor Kumar Sadasivuni, Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review, Life Sciences, Volume 352, 2024, 122899.
6. Wang S, Chen Y, Guo J, Huang Q. Liposomes for Tumor Targeted Therapy: A Review. Int J Mol Sci. 2023 Jan 31;24(3):2643.
7. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51.
8. Waheed I, Ali A, Tabassum H, Khatoon N, Lai WF, Zhou X. Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol. 2024 Apr 10;14:1296091. doi: 10.3389/fonc.2024.1296091.
9. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011 Sep 1;3(3):1377-1397.
10. Thomas RG, Surendran SP, Jeong YY. Tumor Microenvironment-Stimuli Responsive Nanoparticles for Anticancer Therapy. Front Mol Biosci. 2020 Dec 18;7:610533. doi: 10.3389/fmolb.2020.610533. Erratum in: Front Mol Biosci. 2021 May 06;8:693909.
11. Sartaj A, Qamar Z, Qizilbash FF, Annu, Md S, Alhakamy NA, Baboota S, Ali J. Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations. Polymers (Basel). 2021 Dec 15;13(24):4400. doi: 10.3390/polym13244400.
12. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014 Jul;6(3):139-50.
13. Raj Kumar, Guruprasad Reddy Pulikanti, Konathala Ravi Shankar, Darsi Rambabu, Venkateswarulu Mangili, Lingeshwar Reddy Kumbam, Prateep Singh Sagara, Nagaraju Nakka, Midathala Yogesh, 9 - Surface coating and functionalization of metal and metal oxide nanoparticles for biomedical applications, Editor(s): Kunal Mondal, In Metal Oxides, Metal Oxides for Biomedical and Biosensor Applications, 2022, Pages 205-231.
14. Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer. Int J Mol Sci. 2018 Oct 20;19(10):3264. doi: 10.3390/ijms19103264.
15. Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jul;9(4):10.1002/wnan.1449.
16. Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F, Corsi F, Mazzucchelli S. HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. Cancers (Basel). 2022 May 13;14(10):2424.
17. Li M, Zhao G, Su WK, Shuai Q. Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery. Front Chem. 2020 Jul 30;8:647.
18. Pivetta TP, Botteon CEA, Ribeiro PA, Marcato PD, Raposo M. Nanoparticle Systems for Cancer Phototherapy: An Overview. Nanomaterials (Basel). 2021 Nov 20;11(11):3132.
19. Nasim Ebrahimi, Mahdokht Sadat Manavi, Ahmad Nazari, Amirali Momayezi, Ferdos Faghihkhorasani, Al-Hasnawi Rasool Riyadh Abdulwahid, Fatemeh Rezaei-Tazangi, Mohammed Kavei, Roya Rezaei, Halimeh Mobarak, Amir Reza Aref, Wei Fang, Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology, Environmental Research, Volume 239, Part 2, 2023, 117263.
20. Zhou L, Zou M, Xu Y, Lin P, Lei C, Xia X. Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics. Front Oncol. 2022 May 19;12:864301.

21. Kiaie, S.H., Salehi-Shadkami, H., Sanaei, M.J. et al. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. J Nanobiotechnol 21, 339 (2023). https://doi.org/10.1186/s12951-023-02083-y.
22. Chou-Yi Hsu, Ahmed Mahdi Rheima, Mustafa M. Kadhim, Nada Nadhim Ahmed, Srwa Hashim Mohammed, Fatima Hashim Abbas, Zainab Talib Abed, Zahra Muhammed Mahdi, Zainab Sabri Abbas, Safa K. Hachim, Farah K. Ali, Zaid H Mahmoud, Ehsan Kianfar, An overview of nanoparticles in drug delivery: Properties and applications, South African Journal of Chemical Engineering, Volume 46, 2023, Pages 233-270.
23. Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193.
24. Adepu S, Ramakrishna S. Controlled drug delivery systems: Current status and future directions. Molecules. 2021;26(19).
25. Majeed H, Gupta V. Adverse Effects of Radiation Therapy. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
26. Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI. Targeting drug chemo-resistance in cancer using natural products. Biomedicines. 2021;9(10).
27. Afzal O, Altamimi ASA, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in drug delivery: From history to therapeutic applications. Nanomaterials (Basel). 2022;12(24).
28. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–24.
29. Jin C, Wang K, Oppong-Gyebi A, Hu J. Application of nanotechnology in cancer diagnosis and therapy - A mini-review. Int J Med Sci. 2020;17(18):2964–73.
30. Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics. 2022;6(4):400–23.
31. Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: From Chemical-physical applications to nanomedicine. Molecules. 2019;25(1).
32. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7(7):193.
33. Martinez-Pacheco S, O'Driscoll L. Pre-clinical in vitro models used in cancer research: results of a worldwide survey. Cancers. 2021;13(23):6033.
34. Unnikrishnan K, Thomas LV, Ram Kumar RM. Advancement of scaffold-based 3D cellular models in cancer tissue engineering: an update. Front Oncol. 2021;11:733652.
35. Gu M, Wang X, Toh TB, Chow EK-H. Applications of stimuli-responsive nanoscale drug delivery systems in translational research. Drug Discov Today. 2018;23(5):1043–52.
36. Ke X, Shen L. Molecular targeted therapy of cancer: the progress and future prospect. Front Lab Med. 2017;1(2):69–75.
37. Shi X, Tian Y, Liu Y, Xiong Z, Zhai S, Chu S, et al. Research progress of photothermal nanomaterials in multimodal tumor therapy. Front Oncol. 2022;12.
38. Wilkes GM. Targeted therapy: attacking cancer with molecular and Immunological targeted agents. Asia Pac J Oncol Nurs. 2018;5(2):137–55.
39. Shuel SL. Targeted cancer therapies: clinical pearls for primary care. Can Fam Physician. 2022;68(7):515–8.
40. Zhou F, Nordquist RE, Chen WR. Photonics immunotherapy — a novel strategy for cancer treatment. J Innov Opt Health Sci. 2016;9:1–11.
41. Almeida JPM, Figueroa ER, Drezek RA. Gold nanoparticle mediated cancer immunotherapy. Nanomed NBM. 2014;10:503–514. doi: 10.1016/j.nano.2013.09.011.
42. Bear AS, Kennedy LC, Young JK, Perna SK, Mattos Almeida JP, Lin AY, Eckels PC, Drezek RA, Foster AE. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS One. 2013;8:e69073. doi:

10.1371/journal.pone.0069073.

43. Wang C, Xu L, Liang C, Xiang J, Peng R, Liu Z. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 2014;26:8154–8162. doi: 10.1002/adma.201402996.
44. Andersson H, Kim Y-S, O'Neill B, Shi Z-Z, Serda R. HSP70 promoter-driven activation of gene expression for immunotherapy using gold nanorods and near infrared light. Vaccines. 2014;2:216–227. doi: 10.3390/vaccines2020216.
45. Burga RA, Patel S, Bollard CMY, Cruz CR, Fernandes R. Conjugating prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy. Nanomedicine. 2016;11:1759–1767. doi: 10.2217/nnm-2016-0160.
46. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1–6. doi: 10.1016/j.coi.2015.10.009.
47. Choi MR, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, Badve S, Sturgis J, Robinson JP, Bashir R, et al. A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 2007;7:3759–3765. doi: 10.1021/nl072209h.
48. Zhang J, Xia F, Yang Y, Yue C, Zhang C, Yang Y, Ma L, Alfranca G, Liu Y, Hou Y, et al. Human CIK cells loaded with gold nanoprisms as theranostic platform for targeted photoacoustic imaging and enhanced immuno-photothermal combined therapy. Nanoscale Res Lett. 2016;8:109–124. doi: 10.1186/s11671-016-1468-8.
49. Immuno-photothermal E. Human CIK cells loaded with gold nanoprisms as theranostic platform for targeted photoacoustic imaging and enhanced immuno-photothermal combined therapy. Nano Biomed Eng. 2016;8:109–124.